Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole

被引：306

作者：

Imhof, A

Balajee, SA

Fredricks, DN

Englund, JA

Marr, KA

机构：

[1] Fred Hutchinson Canc Res Ctr, Program Infect Dis, Div Clin Res, Seattle, WA 98109 USA

[2] Univ Washington, Dept Med, Seattle, WA USA

[3] Univ Washington, Dept Pediat, Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 39卷 / 05期

关键词：

D O I：

10.1086/423274

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Infection with voriconazole-resistant fungi may become problematic, because organisms with decreased susceptibility have been noted. Breakthrough fungal infections occurred in 13 of 139 patients who received voriconazole at our center during the period of September 1998 through September 2003. Zygomycetes were found in 6 patients, and Candida glabrata bloodstream infection occurred in 4 patients. Minimal inhibitory concentrations were greater than or equal to1 mug/mL for all available isolates. Yeasts and molds with decreased susceptibility to voriconazole may cause invasive infection in patients treated successfully for aspergillosis.

引用

页码：743 / 746

页数：4

共 25 条

[1] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
Ally, R
Schürmann, D
Kreisel, W
Carosi, G
Aguirrebengoa, K
Dupont, B
Hodges, M
Troke, P
Romero, AJ
[J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) : 1447 - 1454
[2] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
Ascioglu, S
Rex, JH
de Pauw, B
Bennett, JE
Bille, J
Crokaert, F
Denning, DW
Donnelly, JP
Edwards, JE
Erjavec, Z
Fiere, D
Lortholary, O
Maertens, J
Meis, JF
Patterson, TF
Ritter, J
Selleslag, D
Shah, PM
Stevens, DA
Walsh, TJ
[J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) : 7 - 14
[3] In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, E
Meletiadis, J
Mouton, JW
Meis, JFGM
Verweij, PE
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) : 45 - 52
[4] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, DW
Ribaud, P
Milpied, N
Caillot, D
Herbrecht, R
Thiel, E
Haas, A
Ruhnke, M
Lode, H
[J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) : 563 - 571
[5] In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi
Espinel-Ingroff, A
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (03) : 954 - 958
[6] Groll AH, 2002, SWISS MED WKLY, V132, P303
[7] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
Herbrecht, R
Denning, DW
Patterson, TF
Bennett, JE
Greene, RE
Oestmann, JW
Kern, WV
Marr, KA
Ribaud, P
Lortholary, O
Sylvester, R
Rubin, RH
Wingard, JR
Stark, P
Durand, C
Caillot, D
Thiel, E
Chandrasekar, PH
Hodges, MR
Schlamm, HT
Troke, PF
de Pauw, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) : 408 - 415
[8] Antifungal activity of the new azole UK-109, 496 (voriconazole)
Kappe, R
[J]. MYCOSES, 1999, 42 : 83 - 86
[9] Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients
Marr, KA
Carter, RA
Crippa, F
Wald, A
Corey, L
[J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (07) : 909 - 917
[10] Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants
Marty, FM
Cosimi, LA
Baden, LR
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (09) : 950 - 952

← 1 2 3 →